Journal article
Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes
PJ Crack, M Zhang, MC Morganti-Kossmann, AJ Morris, JM Wojciak, JK Fleming, I Karve, D Wright, M Sashindranath, Y Goldshmit, A Conquest, M Daglas, LA Johnston, RL Medcalf, RA Sabbadini, A Pébay
Journal of Neuroinflammation | BIOMED CENTRAL LTD | Published : 2014
Abstract
Background: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury.Findings: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower ..
View full abstractRelated Projects (1)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
The authors thank Mr Duncan Crombie (Centre for Eye Research Australia and University of Melbourne) for his technical assistance. This work was supported by a National Health and Medical Research Council of Australia Project Grant 628391 (PJC), a NHMRC Career Development Award Fellowship (AP), a Transport Accident Commission project grant (AP), the ANZ Trustees Program - Medical Research & Technology in Victoria - William Buckland Foundation (AP), the United States National Institutes of Health (1R43CA132395-01A2 to RM), an Australian Research Council Future Fellowship (PJC), a University of Melbourne Collaboration Grant and the Victorian State Government's Department of Innovation, Industry and Regional Development's Operational Infrastructure Support Program.